ABBVIE-M24-209
Phase I
OPEN TO ACCRUAL
An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis
BEIGENE-BGB-11417-105
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
CELGENE-GC-LTFU-001
Phase II/III
OPEN TO ACCRUAL
Long-Term Follow-Up Protocol for Subjects Treated with Gene-Modified T Cells
COLUMBIAUNIVERSITY-AAAT8639
Phase I/II
OPEN TO ACCRUAL
An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis
EMN30-64007957MMY3003-MAJESTEC
Phase III
OPEN TO ACCRUAL
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)
ICHNOS-ISB-2001-101
Phase I
OPEN TO ACCRUAL
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma
IIT-AKHTAR-CILTA-TALQ
Phase I
OPEN TO ACCRUAL
A Phase Ib Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma
JNJ-MY4002-CARTINUE-LTFU
Phase IV
OPEN TO ACCRUAL
Long-Term Follow-Up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
MODERNA-MRNA-2808-P101
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, Open-Label, Multicenter Study of mRNA-2808 in Participants with Relapsed or Refractory Multiple Myeloma
PFIZER-C1071030
Phase I
OPEN TO ACCRUAL
A Phase 1b, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
SWOG-S2213
Phase III
OPEN TO ACCRUAL
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
UAB-21107-MASTER-2-MM
Phase II
OPEN TO ACCRUAL
MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial